Highly active neutral ruthenium(II) arene complexes: Synthesis, characterization, and investigation of their anticancer properties

Synthesis, structural characterization and cytotoxic activity of ternary copper(II)–dipeptide–phenanthroline complexes. A step towards the development of new copper compounds for the treatment of cancer

“…Moreover, C3 induces MCF-7 cell death at an IC 50 = 1 μM being more active than Cisplatin which Table 4 Wavenumber (cm −1 ) of common bands in the complexes and in the free phen, as well as their tentative vibrational assignment. was shown to induce cytotoxicity at IC 50 = 2 μM at 96 h of treatment for the same cell line [41].…”

Ruthenium complex Λ-WH0402 induces hepatocellular carcinoma LM6 (HCCLM6) cell death by triggering the Beclin-1-dependent autophagy pathway

“…[2][3][4] An estimated 70% of tumor-affected patients are receiving platinum-based drugs as part of their treatment. 10 In particular, ruthenium based anticancer drugs have gained significant prominence. 10 In particular, ruthenium based anticancer drugs have gained significant prominence.…”

“…Moreover, ruthenium complexes based anticancer drugs, such as NAMI-A and KP1019, have successfully reached human clinical trials and Ru(II) arene complexes, for instance RAPTA-complexes, have shown excellent in vitro results. Among them, ruthenium complex L-bipyridine 2-(2-trifluoromethphenyl) imidzole [4,5-f ] [1,10] phenanthroline ruthenium(II) chloride (L-[Ru(bpy) 2 -(o-tFPIP)](Cl) 2 Á2H 2 O, L-WH0402) was found to have the best activity among a number of chiral ruthenium complexes. 2,16,17 Furthermore, because most of the biological molecules are chiral, optical isomers of metallic complexes would interact differently with them and, therefore, different biological effects with a chiral molecule such as DNA should be observed.…”

Binuclear dichlorido(η6‐p‐cymene)ruthenium(II) complexes with bis(nicotinate)‐ and bis(isonicotinate)‐polyethylene glycol ester ligands

“…Therefore, in vitro examination of the cytotoxic activity of diverse transition metal complexes has been, and still is, a very important and active field in medicinal chemistry during the last two decades . Ruthenium‐based anticancer drugs deserve a special position in research not only because of their good cytotoxicity but also because of their antimetastatic activity . Especially, several ruthenium complexes combine good selectivity between normal and tumour cells with activity against cisplatin‐resistant tumour cell lines .…”

“…Recently, Steinborn et al investigated neutral and cationic arene ruthenium(II) complexes having κ P and κ P ,κ S respectively coordinated ω‐diphenylphosphino‐functionalized alkylphenyl sulfide, sulfoxide and sulfone ligands (Fig. D and E) . Several complexes from both groups exhibited in vitro cytotoxicities similar to or greater than that of cisplatin.…”